Zilola (levocetirizine) coated tablets 5 mg. №28

$13.80

Manufacturer: Poland

Symptomatic treatment of allergic rhinitis, including year-round allergic rhinitis; chronic idiopathic urticaria.

Description

Zilola (levocetirizine) coated tablets 5 mg. №28

Composition

active substance: levocetirizine;

1 film-coated tablet contains 5 mg of levocetirizine dihydrochloride;

Excipients: microcrystalline cellulose (type 102), lactose monohydrate, colloidal anhydrous silica, magnesium stearate;

shell: opadri white (hypromellose (E 464), titanium dioxide (E 171), macrogol 400).

Dosage form

Film-coated tablets.

Main physical and chemical properties: white or almost white, oblong, biconvex, film-coated tablets, engraved with “R23” on one side. Length about 8 mm, width about 4.5 mm.

Pharmacotherapeutic group

Antihistamines for systemic use. Piperazine derivatives. ATX code R06A E09.

Pharmacological properties

Is an anti-allergic drug. Contains the active R-enantiomer of cetirizine, belonging to the group of histamine antagonists. Its action is due to its ability to block histamine (h1) receptors. Affects the histamine-dependent phase of allergy development, reducing vascular permeability, eosinophil migration, limiting the release of other inflammatory mediators. The drug prevents the development or alleviates the course of allergies, relieving itching, swelling, redness and other manifestations

Indications

Zilola is prescribed for symptomatic treatment (elimination of manifestations):

  • year-round (persistent) allergic rhinitis, accompanied by nasal congestion, sneezing, rhinorrhea (watery discharge), tearing, redness of the conjunctiva;
  • seasonal (intermittent) allergic rhinitis (hay fever, hay fever);
  •  СIU (chronic idiopathic urticaria);
  •  allergic dermatosis, accompanied by itching, rashes.

Contraindications

Do not use Zilola:

  •  in case of intolerance to levocetirizine, any other component of the drug (see the list in the insert);
  •  in case of intolerance to piperazine derivatives;
  • at a chronic kidney disease at the IV (terminal) stage.

Use during pregnancy and breastfeeding
Zilola is not prescribed to pregnant or nursing mothers (cetirizine passes into milk).

Method of application and dose

The tablets are administered orally (swallowed). Admission does not depend on food.
Standard dosage: adults, children older than 6 years are prescribed 5 mg (one tablet) x1 times / day
The maximum dose that can be taken per day is 10 mg (2 tablets).
The duration of use depends on the indications. Treatment is stopped when the symptoms disappear.
In the case of a stable course, continuous therapy may be prescribed during contact with allergens. In chronic forms of the disease, the duration of treatment can be up to 1 year.

Overdose

Symptoms of overdose: in adults – drowsiness, agitation, in children – increased irritability with the transition to drowsiness.
Treatment of overdose: shortly after taking the drug consider the need for gastric lavage. It is recommended to take sorbents (activated charcoal), symptomatic, supportive therapy. Hemodialysis is not used.

Side effects:

  • From the nervous system: drowsiness, headache, fatigue, weakness, asthenia, convulsions, paresthesia, dizziness, fainting, tremor, dysgeusia.
  • From the psyche: sleep disorders, aggression, agitation, hallucinations, depression, insomnia, suicidal thoughts.
  • From the eyes: visual impairment, blurred vision.
  • From the organs of hearing and balance: vertigo.
  • From the cardiovascular system: palpitations, tachycardia.
  • From the respiratory system: shortness of breath.
  • From the gastrointestinal tract: diarrhea, vomiting, constipation, dry mouth, nausea, abdominal pain.
  • From the hepatobiliary system: hepatitis.
  • On the part of the skin and subcutaneous tissue: angioneurotic edema, persistent drug-induced rash, pruritus, rash, urticaria.
  • From the musculoskeletal system: muscle pain, arthralgia.
  • From the immune system: hypersensitivity, including anaphylaxis.
  • From the kidneys and urinary system: dysuria, urinary retention.
  • From nutrition and metabolism: increased appetite.
  • General disorders and administration site conditions: Edema.